Clinical Trial Update: Study of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Steroid Therapy [Phase 2]

View source ↗

Summary

A Phase 2 study of IDN-6556 (emricasan) in patients with severe alcoholic hepatitis who have contraindications to steroid therapy was terminated, with results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alcoholic Hepatitis

Drugs mentioned

• IDN-6556

Snippet

Sponsor: Conatus Pharmaceuticals Inc. | Conditions: Alcoholic Hepatitis | Phase 2 | Status: TERMINATED | Results posted: 2016-11-04